Radioactive bullet targets tough prostate cancer in major trial
NCT ID NCT04689828
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a radioactive drug called 177Lu-PSMA-617 in 469 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers compare it to switching to another hormone therapy. The main goal is to see if it delays cancer growth or improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells)
What this could lead to
If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy, potentially delaying disease progression.
What could go wrong
This is a late-stage trial, but results are not yet final. The drug may not improve survival or could cause side effects like bone marrow suppression or kidney damage. It is only for men whose tumors show a specific marker on a PET scan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Med Ctr
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Duke Univ Medical Center
Durham, North Carolina, 27710, United States
-
Medical College Of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
Mount Sinai Hosp Med School
New York, New York, 10029, United States
-
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York, 10016, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68154, United States
-
Novartis Investigative Site
Innsbruck, Tyrol, 6020, Austria
-
Novartis Investigative Site
Linz, 4020, Austria
-
Novartis Investigative Site
Vienna, 1090, Austria
-
Novartis Investigative Site
Roeselare, West-Vlaanderen, 8800, Belgium
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
Liège, 4000, Belgium
-
Novartis Investigative Site
Vancouver, British Columbia, V5Z 4E6, Canada
-
Novartis Investigative Site
Montreal, Quebec, H2W 1T8, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
Olomouc, 779 00, Czechia
-
Novartis Investigative Site
Angers, 49055, France
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Clermont-Ferrand, 63011, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Paris, 75970, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
München, 80377, Germany
-
Novartis Investigative Site
Nijmegen, Gelderland, 6500HB, Netherlands
-
Novartis Investigative Site
Maastricht, Limburg, 6229 HX, Netherlands
-
Novartis Investigative Site
Utrecht, 3584 CX, Netherlands
-
Novartis Investigative Site
Gliwice, Silesian Voivodeship, 44-101, Poland
-
Novartis Investigative Site
Bratislava, 83310, Slovakia
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Majadahonda, Madrid, 28222, Spain
-
Novartis Investigative Site
El Palmar, Murcia, 30120, Spain
-
Novartis Investigative Site
Pamplona, Navarre, 31008, Spain
-
Novartis Investigative Site
Valencia, Valencia, 46009, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Barcelona, 08041, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Gothenburg, 413 45, Sweden
-
Novartis Investigative Site
Lund, 221 85, Sweden
-
Novartis Investigative Site
Stockholm, 17176, Sweden
-
Novartis Investigative Site
Baden, 5404, Switzerland
-
Novartis Investigative Site
Lausanne, 1011, Switzerland
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
Novartis Investigative Site
Guildford, Surrey, GU2 7XX, United Kingdom
-
Novartis Investigative Site
Sutton, Surrey, SM2 5PT, United Kingdom
-
Novartis Investigative Site
Coventry, CV2 2DX, United Kingdom
-
Novartis Investigative Site
London, EC1A 7BE, United Kingdom
-
Novartis Investigative Site
London, NW1 2BU, United Kingdom
-
Novartis Investigative Site
London, NW3 2QG, United Kingdom
-
Novartis Investigative Site
Middlesbrough, TS4 3BW, United Kingdom
-
Onco Hemato Asso of SW Virginia
Roanoke, Virginia, 24014, United States
-
Rocky Mountain Cancer Centers
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43221, United States
-
Tulane Uni Health Sciences Center
New Orleans, Louisiana, 70112, United States
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
Urology Cancer Center PC
Omaha, Nebraska, 68130, United States
-
Utah Cancer Specialists
Salt Lake City, Utah, 84106, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
WA Uni School Of Med
St Louis, Missouri, 63110, United States